Business, energy, technology, markets and global industry news from Business News Today

RASONQUE

PharmaDeviceNews RASONQUE
Revolution Medicines’ RASONQUE has become the first broad RAS-targeted therapy approved for metastatic pancreatic cancer after a major overall-survival benefit in RASolute 302. Representative image.
Features & Analysis

Revolution Medicines cut the risk of death by 60% with daraxonrasib. How far can the RAS platform expand?

Revolution Medicines’ RASONQUE has become the first broad RAS-targeted therapy approved for metastatic pancreatic adenocarcinoma after Phase 3 data showed a 60% reduction in the risk of death compared with chemotherapy. The approval matters well beyond one cancer because it tests whether RAS, long regarded as one of oncology’s hardest targets, can support an entire

Read More
Pharma & Biotech

Scientists spent decades calling RAS almost undruggable. Rasonque just changed the pancreatic cancer equation

Revolution Medicines has secured FDA approval for Rasonque, or daraxonrasib, after a 500-patient Phase 3 trial showed median survival of 13.2 months compared with 6.7 months on chemotherapy in previously treated metastatic pancreatic cancer.

Read More
Pharma & Biotech

FDA approves RASONQUE after 500-patient trial nearly doubles pancreatic cancer survival

Revolution Medicines’ once-daily daraxonrasib improved median overall survival to 13.2 months from 6.7 months with chemotherapy in RASolute 302, giving metastatic pancreatic adenocarcinoma its first FDA-approved broad RAS-targeted therapy.

Read More